Please ensure Javascript is enabled for purposes of website accessibility

Why Opko Health Is Tanking Today

By Keith Speights – Updated Apr 19, 2019 at 10:09AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A convertible senior note offering and related issuing of new shares caused the healthcare stock to plunge.

What happened

Shares of Opko Health (OPK -3.46%) were tanking 19.6% as of 11:28 a.m. EST on Tuesday. The big drop followed the company's pricing of its offering of $200 million in convertible senior notes. Opko will also issue up to 30 million new shares in connection with the note offering to lend to Jefferies. Purchasers of the convertible senior notes will be able to borrow shares from Jefferies and sell those shares to create a hedge on their investments in the notes.  

So what

Companies issue convertible senior notes all the time to raise money without the transactions taking a significant toll on their stock prices. The problem for Opko Health came from its move to issue a large number of new shares in connection with its notes offering.

Man looking at chart going down

Image source: Getty Images.

Issuing new shares caused Opko stock to tank primarily because it will dilute the value of existing shares. Opko's stock float -- the number of shares available for trading -- is around 309 million shares. Adding another 30 million shares to the mix makes all of those current shares worth less.

Investors also probably don't get a warm and fuzzy feeling from Opko's need to issue new shares to attract buyers for its convertible senior notes. Most note offerings don't require this kind of "sweetener" to make the deal attractive for buyers.

The transaction is a little complicated, but it reduces the risk for buyers of Opko's notes. An individual who buys the convertible senior notes could be hurt if Opko's share price drops over the next few years, making the option of converting the notes to Opko shares essentially worthless.

But the buyer of the notes can borrow shares from Jefferies (which in turn is borrowing the newly issued shares from Opko) and sell those shares, creating a short position in Opko. If Opko's share price falls, the buyer of the notes will be insulated from the negative impact on the value of the convertible senior notes because the short position will increase in value.

Check out the latest Opko earnings call transcript.

Now what

All of the problems created by Opko offering convertible senior notes and issuing new shares in connection with the move will go away if the company achieves strong growth that drives its share price up. However, the prospects for that happening don't seem to be very good right now.

Opko's revenue grew only 1.5% year over year in the third quarter of 2018. Its bottom line improved a little, but the company still posted a net loss of $0.05 per diluted share. Although several Wall Street analysts remain optimistic about Opko Health, most investors will probably want to stay away until the company shows that it can turn things around.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

OPKO Health, Inc. Stock Quote
OPKO Health, Inc.
$1.81 (-3.46%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.